New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 12, 2012
10:00 EDTHES, VNO, NKTR, JCP, CAT, PBR, VRTX, KRC, GRMN, BMY, STRA, JNJ, IQNTOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Caterpillar (CAT) downgraded to Neutral from Overweight at JPMorgan... Garmin (GRMN) downgraded to Sell from Neutral at Goldman... Inteliquent (IQNT) downgraded to Underweight from Equal Weight at Morgan Stanley... J.C. Penney (JCP) downgraded to Underperform from Neutral at Credit Suisse... Johnson & Johnson (JNJ) downgraded to Hold from Buy at Jefferies... Kilroy Realty (KRC) downgraded to Neutral from Buy at BofA/Merrill... Nektar (NKTR) downgraded to Hold from Buy at Jefferies... Strayer Education (STRA) downgraded to Neutral from Overweight at JPMorgan... Vertex (VRTX) downgraded to Neutral from Outperform at Credit Suisse... Vornado (VNO) downgraded to Neutral from Buy at BofA/Merrill... Bristol-Meyers (BMY) downgraded to Market Perform from Outperform at BMO Capital... Petrobras (PBR) downgraded to Neutral from Buy at BofA/Merrill... Hess Corp. (HES) downgraded to Market Perform from Outperform at Howard Weil.
News For CAT;IQNT;GRMN;JCP;JNJ;KRC;NKTR;STRA;VRTX;VNO;BMY;PBR;HES From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
May 12, 2015
16:16 EDTVRTXVertex confirms FDA panel voted 12-to-1 to recommend approval of Orkambi
16:16 EDTVRTXPiper Jaffray remains confident in approval for Vertex
Subscribe for More Information
16:01 EDTJCPOptions Update; May 12, 2015
Subscribe for More Information
15:43 EDTVRTXFDA panel votes 12 to 1 that data supports Orkambi approval
Subscribe for More Information
15:35 EDTVRTXFDA panel votes unanimously that data support Orkambi safety
Subscribe for More Information
15:32 EDTVRTXFDA panel inconclusive on if Lumacaftor contributes to Orkambi effectiveness
Subscribe for More Information
12:37 EDTSTRAFor-profit education stocks slide after SEC charges ITT with fraud
Subscribe for More Information
11:37 EDTJCPStocks with call strike movement; TWTR JCP
Subscribe for More Information
10:23 EDTVRTXVertex shares halted while FDA panel meeting takes place
07:58 EDTVRTXFDA Pulmonary-Allergy Drugs Advisory Committee to hold a meeting
Subscribe for More Information
May 11, 2015
17:58 EDTJNJJ&J's Janssen gets complete response letter regarding sNDA for Invega Sustenna
Subscribe for More Information
16:00 EDTJCPOptions Update; May 11, 2015
Subscribe for More Information
10:14 EDTCATAnalyst says buy Caterpillar, Joy Global before mining bottoms
The shares of Joy Global (JOY) and Caterpillar (CAT) are climbing after research firm Baird analyst Mircea Dobre upgraded both names, citing a potential bottom in commodity prices. Both companies develop mining equipment. WHAT'S NEW: In a note to investors earlier today, Baird's Dobre upgraded Joy Global and Caterpillar to Outperform from Market Perform. There are signs that the worst of the downturn in commodity prices may have passed, the analyst stated. Additionally, the shares of both Caterpillar and Joy Global historically bottom three to five quarters before mining equipment shipments rebound, according to Dobre. Consequently, investors who wait for evidence of a turnaround in the companies' mining equipment bookings may be late to the party, the analyst warned. Both stocks have now underperformed the market by amounts that are similar to their worst underperfomance during the early 1980s commodity bust, according to Dobre, who raised the price target on Caterpillar to $101 from $80 and on Joy Global to $62 from $45. PRICE ACTION: In early trading, Joy Global climbed nearly 4% to $43.64 and Caterpillar rose 1.5% to $88.60.
09:59 EDTCATOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Alcatel-Lucent (ALU) upgraded to Outperform from Neutral at Exane BNP Paribas... Caterpillar (CAT) upgraded to Outperform at Baird... Cisco (CSCO) upgraded to Outperform with $36 target at Pacific Crest... Evolution Petroleum (EPM) upgraded to Outperform from Market Perform at Northland... Hecla Mining (HL) upgraded on hedging discipline at Roth Capital... Joy Global (JOY) upgraded to Outperform from Neutral at Baird... Monster Beverage (MNST) upgraded to Buy from Neutral at Citigroup... Nokia (NOK) upgraded to Outperform from Neutral at Exane BNP Paribas... On Deck Capital (ONDK) upgraded to Neutral from Sell at Sterne Agee CRT... Royal Caribbean (RCL) upgraded to Outperform from Neutral at Wedbush... SMC (SMECF) upgraded to Buy from Neutral at Goldman... Sally Beauty (SBH) upgraded to Outperform from Market Perform at Raymond James... Southwestern Energy (SWN) upgraded to Overweight from Equal Weight at Barclays... Sprouts Farmers Markets (SFM) upgraded to Outperform at BMO Capital... Suburban Propane (SPH) upgraded on positive outlook at Stifel... Suffolk Bancorp (SUBK) upgraded to Outperform from Market Perform at Keefe Bruyette... Syngenta (SYT) upgraded to Buy from Neutral at UBS... Triumph Group (TGI) upgraded to Outperform from Sector Perform at RBC Capital... United Natural Foods (UNFI) upgraded to Overweight from Equal Weight at Stephens... Web.com (WWWW) upgraded to Buy from Hold at Deutsche Bank... Zillow Group (Z) upgraded to Buy from Neutral at SunTrust.
09:02 EDTCATCaterpillar upgraded to Outperform at Baird
As reported previously, Baird upgraded Caterpillar to Outperform from Neutral as the firm noted the stock's meaningful underperformance over the past four years and its history of having never underperformed the broader market for five consecutive years. Baird raised its price target to $101 from $80 on Caterpillar shares.
07:40 EDTVRTXFocus on Vertex will shift to pricing after Orkambi FDA meeting, WSJ says
An FDA advisory committee that meets Tuesday to decide whether to recommend approval of Vertexís Orkambi will be closely watched by health insurers and pharmacy-benefit managers concerned that the experimental cystic-fibrosis drug will be high-priced, said The Wall Street Journal. Vertex hasnít announced a price, but analyst at JPMorgan predict the drug will have a wholesale price of about $287,000 annually per patient. Publicly traded PBM owners include Catamaran (CTRX), which is being acquired by UnitedHealth (UNH), CVS Health (CVS) and Express Scripts (ESRX). Reference Link
06:23 EDTCATCaterpillar upgraded to Outperform from Neutral at Baird
May 10, 2015
19:25 EDTJNJCourt rejects claim that drugmakers misled opiate patients, Bloomberg says
Subscribe for More Information
17:13 EDTPBRPetrobras seesk $152M in graft lawsuit, WSJ says
Subscribe for More Information
14:05 EDTJNJJohnson & Johnson shares may deliver double-digit returns, Barron's says
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use